Novo Nordisk, type 2 diabetes
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups,
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other best stocks to buy ...
Hosted on MSN6d
European Countries Are Cracking Down on Weight-Loss Drugs Like Wegovy—Could the U.S. Follow?Novo Nordisk, the pharmaceutical company behind the world’s most popular weight-loss injections, is expanding its global ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback